Tuberculosis in Pregnancy: A Review

Tuberculosis (TB) was declared a public health emergency by WHO in 2005. The disease is a significant contributor to maternal mortality and is among the three leading causes of death among women aged 15–45 years in high burden areas. The exact incidence of tuberculosis in pregnancy, though not readily available, is expected to be as high as in the general population. Diagnosis of tuberculosis in pregnancy may be challenging, as the symptoms may initially be ascribed to the pregnancy, and the normal weight gain in pregnancy may temporarily mask the associated weight loss. Obstetric complications of TB include spontaneous abortion, small for date uterus, preterm labour, low birth weight, and increased neonatal mortality. Congenital TB though rare, is associated with high perinatal mortality. Rifampicin, INH and Ethambutol are the first line drugs while Pyrazinamide use in pregnancy is gaining popularity. Isoniazid preventive therapy is a WHO innovation aimed at reducing the infection in HIV positive pregnant women. Babies born to this mother should be commenced on INH prophylaxis for six months, after which they are vaccinated with BCG if they test negative. Successful control of TB demands improved living conditions, public enlightenment, primary prevention of HIV/AIDS and BCG vaccination

eterminants of seizure occurrence in preeclampsia before commencing and during treatment with magnesium sulphate

Background: Eclampsia is considered as a consequence of severe preeclampsia, with magnesium sulphate regarded as gold standard in seizure treatment and prophylaxis. Convulsions have however been noted when criteria for severe preeclampsia were not met and in patients undergoing treatment with magnesium sulphate.Methods: A secondary analysis of data obtained from a prospective cross sectional study, involving assessment of clinical and biochemical markers of preeclampsia including magnesium in 75 patients with severe preeclampsia who were given magnesium sulphate using the Pritchard regimen.Results: Headache (p = 0.002), vomiting (p = 0.005) and prior occurrence of seizures before presentation (p = 0.001), were significant risk factors for occurrence of convulsions. In addition, serum magnesium levels were significantly lower (1.61±0.32 mg/dL) among patients who had seizures than in those who did not (2.01±0.25 mg/dL), (p<0.001). Systolic blood pressure (p = 0.22), diastolic blood pressure (p = 0.29), mean arterial blood pressure (p = 0.17) and proteinuria (p = 0.18) however did not determine the occurrence of seizures. Only 3/49 (6.1%) of the patients with severe hypertension (MAP≥125 mmHg) fitted, compared to 6/26 (23.1%) with mild hypertension (MAP<125mmHg) who convulsed (p = 0.04). Convulsion during treatment with MgS04 was associated with significantly lower levels of serum magnesium (4.04±0.5 mg/dL), than 4.63±0.5 mg/dL observed among patients with severe preeclampsia who did not convulse (p = 0.04).Conclusions: Headache, vomiting, prior convulsion and low serum magnesium levels preceded the occurrence of fits before treatment while, prior convulsion and low serum magnesium level consistently preceded the occurrence of fits during treatment of preeclampsia with magnesium sulphate

Synergistic corrosion inhibition of low carbon steel in HCl and H2SO4 media by 5‐methyl‐3‐ phenylisoxazole‐4‐carboxylic acid and iodide ions.

The inhibition performance of 5‐methyl‐3‐phenylisoxazole‐4‐carboxylic acid (MPC) alone and in combination with potassium iodide (KI) for low carbon steel in 1.0 M HCl and H2SO4 solutions is studied using weight loss, potentiodynamic polarization (PDP), electrochemical impedance spectroscopy (EIS), linear polarization resistance (LPR), ultraviolet–visible (UV–vis) spectrophotometry, and surface observation methods. The influence of solution temperature on the performance of MPC and MPC + KI is also investigated. Results obtained indicate that the optimum concentration of MPC in 1.0 M HCl and H2SO4 solutions is 500 and 50 mg/L, respectively. The maximum inhibition at the optimum concentrations of MPC in HCl and H2SO4 solutions at 25 °C is 46 and 23%, respectively. Addition of 3 mM KI to 500 mg/L MPC in HCl solution and to 50 mg/L MPC in H2SO4 solution at 25 °C raised the inhibition efficiency to 86 and 89%, respectively. Inhibition efficiency of MPC and MPC + KI increases with rise in solution temperature with MPC + KI inhibition reaching 88 and 91%, respectively in HCl and H2SO4 solutions at 60 °C. Both MPC and MPC + KI acted as a mixed‐type corrosion inhibitor according to the PDP results. Surface examination results confirm the effectiveness of MPC + KI mixture in retarding low carbon steel corrosion in 1.0 M HCl and H2SO4 solutions. It could be profitable utilizing MPC + KI mixture in the formulation of corrosion inhibitor cocktail for acid cleaning operations

Contraceptive uptake among women attending family planning clinic in a Nigerian tertiary health facility: a 6 year review

Background: Contraceptive uptake is one of the most important determinants of pregnancy rates and birth rates in the world. Aim: To determine the principal trends in contraceptive use from 2004-2009 in the family planning unit of a tertiary health centre in South-Western Nigeria, and to identify the effect of age, marital status and parity on the choice of contraceptive method.Methods: The record of 1,862 clients attending the Family Planning unit of Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Osun-State, Nigeria for the period between 2004-2009 were reviewed. Information related to the age, marital status, parity and the choice of contraception were obtained using a structured proforma and the data analyzed with SPSS version 16. Pearson chi-square test was used as test of significance where applicable.Results: Within the study period, the contraceptive uptake was 13.2%. Copper-T IUCD was the most commonly used method of contraception (77.9%), followed by the progestogen only injectable contraceptives (12.6%), then oral pills (4.1%) and progestin implants (2.3%). Single women and women of low parity are more likely to use pills than IUCD (69% vs. 38.3%) while long acting reversible contraception (injectables and IUCD) are preferred by women with higher parity (P=0.000).Conclusions: IUCD is the most popular method of contraception in Ife-Ijesha area of Nigeria. Contraceptive uptake is relatively low among the women. Age and parity are key influences on the uptake and choice of contraception practiced by the women, while the influence of marital status is not statistically significant

Trends in vaginal hysterectomy in a Nigerian teaching hospital: A 14-year review

Background: The procedure of vaginal hysterectomy is a fast disappearing art. This study looks at 14 years’ experience of vaginal hysterectomy in Ile‑Ife, Nigeria.Objectives: To determine and compare the rate, indications, and complications of vaginal hysterectomy over a 14-year period at Ile‑Ife, Nigeria.Methods: The medical records of patients managed with vaginal hysterectomies performed from 1st January 2005 to 31st December 2018 were reviewed. The demographics and indications for vaginal hysterectomy were extracted. Data were analyzed using Statistical Package for Service Solutions – IBM version 22. Frequencies and percentages were calculated and associations compared where applicable using Chi‑square with level of significance set at <0.05.Results: Pelvic organ prolapse accounted for 0.8% of gynecological admissions and vaginal hysterectomy accounted for 2.3% of major  gynaecological operations. The mean age was 66.1 ± 9.2 years with a mean age of menopause of 15.2 ± 7.1 years. The mean parity was 6.2 ± 1.6. Pelvic organ prolapse was the commonest indication. The mean blood loss at surgery was 314.2 ± 184.8 ml. The modal post‑operative complication was post‑operative anemia, and hypertension was the commonest comorbidity. The mean duration of surgery was 3 ± 0.9 h and the mean duration of admission was 5.4 ± 2.7 days.Conclusion: The rate of vaginal hysterectomy is on the decline. This may be due to case under reporting, limiting of family size, or low uptake of farming occupation in our society. Key words: Comorbidities; complications; incidence; indications; vaginal hysterectomy

Developing a core outcome set for future infertility research : An international consensus development study

STUDY QUESTION: Can a core outcome set to standardize outcome selection, collection and reporting across future infertility research be developed? SUMMARY ANSWER: A minimum data set, known as a core outcome set, has been developed for randomized controlled trials (RCTs) and systematic reviews evaluating potential treatments for infertility. WHAT IS KNOWN ALREADY: Complex issues, including a failure to consider the perspectives of people with fertility problems when selecting outcomes, variations in outcome definitions and the selective reporting of outcomes on the basis of statistical analysis, make the results of infertility research difficult to interpret. STUDY DESIGN, SIZE, DURATION: A three-round Delphi survey (372 participants from 41 countries) and consensus development workshop (30 participants from 27 countries). PARTICIPANTS/MATERIALS, SETTING, METHODS: Healthcare professionals, researchers and people with fertility problems were brought together in an open and transparent process using formal consensus science methods. MAIN RESULTS AND THE ROLE OF CHANCE: The core outcome set consists of: viable intrauterine pregnancy confirmed by ultrasound (accounting for singleton, twin and higher multiple pregnancy); pregnancy loss (accounting for ectopic pregnancy, miscarriage, stillbirth and termination of pregnancy); live birth; gestational age at delivery; birthweight; neonatal mortality; and major congenital anomaly. Time to pregnancy leading to live birth should be reported when applicable. LIMITATIONS, REASONS FOR CAUTION: We used consensus development methods which have inherent limitations, including the representativeness of the participant sample, Delphi survey attrition and an arbitrary consensus threshold. WIDER IMPLICATIONS OF THE FINDINGS: Embedding the core outcome set within RCTs and systematic reviews should ensure the comprehensive selection, collection and reporting of core outcomes. Research funding bodies, the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) statement, and over 80 specialty journals, including the Cochrane Gynaecology and Fertility Group, Fertility and Sterility and Human Reproduction, have committed to implementing this core outcome set. STUDY FUNDING/COMPETING INTEREST(S): This research was funded by the Catalyst Fund, Royal Society of New Zealand, Auckland Medical Research Fund and Maurice and Phyllis Paykel Trust. The funder had no role in the design and conduct of the study, the collection, management, analysis or interpretation of data, or manuscript preparation. B.W.J.M. is supported by a National Health and Medical Research Council Practitioner Fellowship (GNT1082548). S.B. was supported by University of Auckland Foundation Seelye Travelling Fellowship. S.B. reports being the Editor-in-Chief of Human Reproduction Open and an editor of the Cochrane Gynaecology and Fertility group. J.L.H.E. reports being the Editor Emeritus of Human Reproduction. J.M.L.K. reports research sponsorship from Ferring and Theramex. R.S.L. reports consultancy fees from Abbvie, Bayer, Ferring, Fractyl, Insud Pharma and Kindex and research sponsorship from Guerbet and Hass Avocado Board. B.W.J.M. reports consultancy fees from Guerbet, iGenomix, Merck, Merck KGaA and ObsEva. C.N. reports being the Co Editor-in-Chief of Fertility and Sterility and Section Editor of the Journal of Urology, research sponsorship from Ferring, and retains a financial interest in NexHand. A.S. reports consultancy fees from Guerbet. E.H.Y.N. reports research sponsorship from Merck. N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. All authors have completed the disclosure form

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Background Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage. Methods In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283. Findings Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65–1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52–0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88–1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group. Interpretation Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset. Funding London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation

Influence of multiple antenatal counselling sessions on modern contraceptive uptake in Nigeria

Objective To determine the influence of multiple contraceptive counselling sessions during antenatal care on use of modern postpartum contraception.Method A total of 216 eligible pregnant women were randomised into antenatal and postnatal counselling groups. The ‘Antenatal group’ received one-to-one antenatal contraceptive counselling on several occasions while the ‘Postnatal group’ received a single one-to-one contraceptive counselling session at the sixth week postnatal check, as is routinely practised. All participants were contacted six months postpartum by telephone or personal visit, and questioned about their contraceptive use, if any.Results More women who had multiple antenatal contraceptive counselling sessions used modern contraceptive methods than those who had a single postnatal counselling session (57% vs. 35%; p = 0.002). There was also a significantly more frequent use of contraception among previously undecided patients in the Antenatal group (p = 0.014).Conclusion Multiple antenatal contraceptive counselling sessions improve the use of modern postpartum contraception

Comparative study of proguanil and sulphadoxine–pyrimethamine in the prevention of malaria in pregnancy

Background: Intermittent preventive treatment of malaria in pregnancy with sulphadoxine–pyrimethamine (SP) is recommended for prevention of malaria in pregnancy. However, chemoprophylaxis with proguanil (PG) is being used in pregnancy for preventing malaria in selected cases. Objective: To compare the efficacy of daily PG and intermittent monthly SP in preventing malaria and its complications during pregnancy. Patients and Methods: This was a prospective comparative study conducted among 270 consenting pregnant women with parity ≤2 at gestational age of 18–24 weeks. Participants were enrolled and randomized to PG or SP group following a baseline hemoglobin estimation and blood film negative for malaria parasite. At 36 weeks of gestation, maternal blood sample was checked for hemoglobin concentration and malaria parasitaemia, and the infant birth weight was assessed at delivery. Statistical Analysis: Appropriate univariate, and bivariate analysis employed and level of significance set at P < 0.05. Results: One hundred and thirty-five participants in each group (246) completed the study. Ten (8.5%) had malaria parasitaemia in the PG group at 36 weeks compared to 15 (11.7%) in the SP group (P = 0.40); 5 (4.3%) in the PG compared with 6 in SP group (4.7%) had anemia (Hb <10 g/dl) at 36 weeks (P = 0.86). In addition, 6 (5.1%) participants in the PG group developed clinical malaria compared to 3 (2.3%) in the SP group (P = 0.25). The mean infant birth weight in the PG and SP groups were 3.05 kg and 3.00 kg, respectively (P = 0.24). Conclusion: PG and SP were comparable in efficacy and outcome for malaria prevention during pregnancy. IPT-SP is recommended for prevention of malaria in pregnancy. However, PG is beneficial in selected patients with known adverse reactions to sulphonamide